Project Grant R01NS147120
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded Vanderbilt University Medical Center $711,408 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project, "Phenotypes and Endotypes of Recovery from Acute Disorders of Consciousness," pursues multimodal neurobiological prediction of recovery outcomes in...
- The National Institute on Aging awarded Yale University $839,400 under the Aging Research program (CFDA 93.866) on September 1, 2026, to validate novel algorithms for assessing sleep deficiency in persons with Alzheimer's disease and related dementias. The project addresses the urgent need for feasible, accurate assessment methods for sleep deficiency in ADRD populations, where over half of patients experience sleep abnormalities that accelerate cognitive and functional decline. Existing...
- The National Institute of Neurological Disorders and Stroke awarded Regents of the University of Michigan $128,358 on February 16, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to explore cholinergic brain activity changes and their associations with sleep alterations in Lewy body disease. The research investigates how cholinergic neurotransmission affects the sleep-wake cycle, particularly rapid eye movement (REM) sleep...
- The National Institute of Neurological Disorders and Stroke awarded Vanderbilt University Medical Center $688,785 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate arousal network dysfunction in temporal lobe epilepsy. The research examines how recurrent consciousness-impairing focal seizures in temporal lobe epilepsy patients affect subcortical arousal networks and contribute to long-term...
- The National Institute on Aging awarded $1.9 million to The General Hospital Corporation (Massachusetts General Hospital) on March 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a multisite longitudinal cohort study examining sleep and circadian rhythm biomarkers in postoperative delirium and neurocognitive recovery. The study, titled Sleep and Circadian Rhythm Biomarkers of Postoperative Neurocognitive Recovery (SLEEP-POD2), will enroll 400 adults over age 65 undergoing...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $420,750 to West Virginia University Research Corporation on August 27, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Project Grant R21NS151357). The award funds research into sleep-driven reorganization of excitatory and inhibitory synaptic nanoarchitecture, investigating how...
- The National Institute on Aging (National Institutes of Health, Department of Health and Human Services) awarded The Regents of the University of California, San Francisco $711,678 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate a gene-environment deviation (GED) framework quantifying the mismatch between observed sleep patterns and genetically predicted sleep preferences in relation to Alzheimer's disease and Alzheimer's disease-related dementias...
- The National Institute on Aging (NIA) awarded Brigham & Women's Hospital Inc. a $2,576,936 Project Grant under the Aging Research federal grant program (CFDA 93.866) to characterize the variability in sleep spindle activity across a population and evaluate the use of sleep spindle dynamics as biomarkers for Alzheimer's disease, mild cognitive impairment, and trisomy 21. The 3-year project will develop statistical models and methods to analyze sleep spindle patterns and their relationship...
- The National Institute of Neurological Disorders and Stroke awarded The Trustees of Columbia University in the City of New York $565,022 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of reactive oxygen species and ferroptosis in frontotemporal dementia. The research will assess mechanisms of neurodegeneration in frontotemporal dementia using in vitro and in vivo models. Work includes...
- The National Institute on Aging awarded The Washington University $578,856 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate how sleep reinforces homeostatic set-points in neural activity and mitigates neurodegenerative disease. The award funds research applying novel computational tools to continuous multi-site recordings of neural activity in P301S mice, a tauopathy model, to test whether sleep enhancement can reinforce criticality—an optimal computational...
The National Institute of Neurological Disorders and Stroke awarded Vanderbilt University Medical Center $648,918 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate sleep-circadian disruption in behavioral variant frontotemporal dementia. The research will examine how sleep-circadian disruption relates to brain changes and symptoms in patients with behavioral variant frontotemporal dementia, the most common form of dementia in adults under age 60. Sleep problems affect up to 76 percent of BVFTD patients and may emerge early in disease progression. Prior research has relied on subjective sleep reports rather than objective measures, used small study populations without control groups, and focused on general brain atrophy rather than specific sleep-wake networks. This study will overcome these limitations through detailed sleep monitoring using wrist-worn activity monitors and portable sleep studies, paired with comprehensive assessment of functional brain imaging, neurofluid biomarkers, and behavioral outcomes in BVFTD patients and age-matched healthy controls. The research will identify whether sleep-circadian disruption contributes to disease progression and may serve as a modifiable therapeutic target. Work is performed at Vanderbilt University Medical Center in Forest Hills, Tennessee, with a period of performance from September 1, 2026, through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $648.9k | 8/21/26 |